<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 29 Drug Therapy Management | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.34.29/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.34.29/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|34|29|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="29"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|34|29" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.34.29"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 29 Drug Therapy Management | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.34.29/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.34.29/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|34" data-search-heading="">
                  <a href="/us/md/exec/comar/10.34" title="Subtitle 34 BOARD OF PHARMACY">Subtitle 34 BOARD OF PHARMACY</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|34|29" data-search-heading="">
                  <span title="Chapter 29 Drug Therapy Management">Chapter 29 Drug Therapy Management</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|34|29">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.34.29">Chapter 29 Drug Therapy Management</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date: December 11, 2003 (30:24 Md. R. 1742)</p>
                  <p>——————</p>
                  <p>Chapter revised effective April 15, 2013 (40:7 Md. R. 611)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.01#B" title="">Regulation .01B</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.02" title=".02 Content of Protocol.">Regulation .02</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.03" title=".03 Content of Prescriber-Pharmacist Agreement.">Regulation .03</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.04" title=".04 Requirements for Participation in Drug Therapy Management.">Regulation .04</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.05" title=".05 Guidelines for Use of Protocols.">Regulation .05</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.06" title=".06 Therapy Management Contracts.">Regulation .06</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.29.07" title=".07 Fees.">Regulation .07</a> amended effective March 28, 2016 (43:6 Md. R. 409)</p>
                  <h2>Authority</h2>
                  <p>Health Occupations Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-6" title="">12-6</a>A-<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=01" title="">01</a> — 12-6A-10, Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.34.29.01" data-order="|10|34|29|.01|" data-ref-path="10|34|29|.01" class="h__section">.01 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(1)">(1)</span> “Amendment” means a change to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(1)(a)">(a)</span> A protocol or prescriber-pharmacist agreement; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(1)(b)">(b)</span> The parties to the prescriber-pharmacist agreement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(2)">(2)</span> “Applicants” means physicians, pharmacists, podiatrists, or certified advanced practice nurses with prescriptive authority submitting a prescriber-pharmacist agreement and protocol to their respective Boards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(2-1)">(2-1)</span> “Authorized prescriber” means a licensed physician, licensed podiatrist, or certified advanced practice nurse with prescriptive authority under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=8-508" title="">Health Occupations Article, §8-508, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(3)">(3)</span> “Boards” means the Board of Physicians, the Board of Pharmacy, the Board of Podiatric Medical Examiners, and the Board of Nursing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(4)">(4)</span> "Condition" means a disease-state or health circumstance necessitating monitoring or intervention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.01#B(5)">(5)</span> "Emergency first care" means triage of emergent conditions or treatment of the condition in those cases in which a protocol specifies treatment for the emergent condition.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.02" data-order="|10|34|29|.02|" data-ref-path="10|34|29|.02" class="h__section">.02 Content of Protocol.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A">A.</span> A protocol shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(1)">(1)</span> Be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(1)(a)">(a)</span> Written; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(1)(b)">(b)</span> Condition or disease-state specific; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)">(2)</span> Contain the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(a)">(a)</span> The condition that the protocol is designed to manage;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(b)">(b)</span> A list of medications that may be used under the auspices of the protocol;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(c)">(c)</span> Monitoring parameters including laboratory tests for the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(c)(i)">(i)</span> Condition; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(c)(ii)">(ii)</span> Medication employed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(d)">(d)</span> A list of circumstances requiring contact with the authorized prescriber or authorized prescribers who are a party to the prescriber-pharmacist agreement;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(e)">(e)</span> A statement prohibiting substitution of a chemically dissimilar drug product by the pharmacist for the product prescribed by the authorized prescriber unless permitted in the therapy management contract;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(f)">(f)</span> A list of circumstances under which the pharmacist may alter doses, modify the treatment regimen, or switch the agent under the terms of the therapy management contract;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(g)">(g)</span> Information to be documented;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(h)">(h)</span> A listing of provisions within the protocol that may be customized within a therapy management contract; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#A(2)(i)">(i)</span> An action plan for situations when the pharmacist encounters a situation that is not addressed in the protocol.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#B">B.</span> A protocol may authorize:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#B(1)">(1)</span> The modification, continuation, and discontinuation of drug therapy;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#B(2)">(2)</span> The ordering of laboratory tests;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#B(3)">(3)</span> Other patient care management measures related to monitoring or improving the outcomes of drug or device therapy; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#B(4)">(4)</span> For protocols by a licensed physician and licensed pharmacist, the initiation of drug therapy under written, disease-state specific protocols.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#C">C.</span> A protocol may not authorize acts that exceed the scope of practice of the parties to the prescriber-pharmacist agreement.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.02#D">D.</span> Technical modifications to the protocol shall be registered with the Board of Pharmacy within 30 days of the technical modification.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.03" data-order="|10|34|29|.03|" data-ref-path="10|34|29|.03" class="h__section">.03 Content of Prescriber-Pharmacist Agreement.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A">A.</span> The prescriber-pharmacist agreement shall contain the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(1)">(1)</span> The names and signatures of the physicians, podiatrists, or certified advanced practice nurses with prescriptive authority and pharmacists authorized to act under a therapy management contract;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(2)">(2)</span> The locations where the pharmacists may provide therapy management services;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(3)">(3)</span> The titles of the protocols to which the prescriber-pharmacist agreement pertains;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(4)">(4)</span> The methods and time frames by which documentation and routine communication will occur between the physicians, podiatrists, or certified advanced practice nurses with prescriptive authority and the pharmacists, including the time frames in which the pharmacist will fully update the patient’s record in writing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(5)">(5)</span> The name, address, and telephone number of the party to the prescriber-pharmacist agreement who is to receive correspondence from the Boards related to the prescriber-pharmacist agreement;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(6)">(6)</span> A statement that the physicians, podiatrists, or certified advanced practice nurses with prescriptive authority and pharmacists shall comply with all State and federal laws relating to patient confidentiality; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#A(7)">(7)</span> A list of devices available to the pharmacists performing under the prescriber-pharmacist agreement, which are relevant to the disease-states or conditions to be managed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#B">B.</span> Technical modifications to the prescriber-pharmacist agreement shall be registered with the Board of Pharmacy within 30 days of the technical modification.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#C">C.</span> The party designated as the contact person to receive correspondence from the Boards shall ensure that the parties to the prescriber-pharmacist agreement are notified in a timely manner of the information received from the Boards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.03#D">D.</span> If the contact information for the party to the agreement designated to receive correspondence from the Boards changes, the designee shall notify the Boards of the change within 30 days of the change.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.04" data-order="|10|34|29|.04|" data-ref-path="10|34|29|.04" class="h__section">.04 Requirements for Participation in Drug Therapy Management.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A">A.</span> In order to enter into a therapy management contract, a pharmacist:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(1)">(1)</span> Shall be licensed by and in good standing with the Board of Pharmacy;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(2)">(2)</span> Shall possess a Doctor of Pharmacy degree or equivalent training as established in <a class="internal-link " href="/us/md/exec/comar/10.34.29.04#B" title="">§B of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(3)">(3)</span> May not have:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(3)(a)">(a)</span> A public final order by the Board of Pharmacy disciplining the pharmacist's license within the 5 years immediately before the application is submitted; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(3)(b)">(b)</span> Limitations placed on the pharmacist's license by the Board of Pharmacy in a public order;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)">(4)</span> Shall possess relevant advanced training as indicated by one of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(a)">(a)</span> Certification as a specialist related to the disease state specified by the protocol by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(a)(i)">(i)</span> The Board of Pharmacy Specialties;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(a)(ii)">(ii)</span> The American Society of Consultant Pharmacist's Certified Geriatric Practitioner certification program; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(a)(iii)">(iii)</span> Another credentialing body approved by the Board of Pharmacy; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(b)">(b)</span> Successful completion of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(b)(i)">(i)</span> A residency accredited by the American Society of Health-Systems Pharmacists, a body approved by the Board of Pharmacy or offered by a body accredited by the Accreditation Council for Pharmacy Education;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(b)(ii)">(ii)</span> A certificate program approved by the Board of Pharmacy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(b)(iii)">(iii)</span> A National Association of Boards of Pharmacy credentialing examination; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(4)(b)(iv)">(iv)</span> An examination approved by the Board of Pharmacy;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(5)">(5)</span> Shall have successfully completed:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(5)(a)">(a)</span> 1,000 hours of relevant clinical experience; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(5)(b)">(b)</span> 320 hours in a structured experience program approved by the Board of Pharmacy; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#A(6)">(6)</span> Shall document training related to the disease state specified in the protocol.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B">B.</span> A pharmacist who does not possess a Doctor of Pharmacy degree shall document that the pharmacist's training has included the following components:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(1)">(1)</span> Designing, implementing, monitoring, evaluating, and modifying or recommending modifications in drug therapy to insure effective, safe, and economical patient care;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(2)">(2)</span> Identifying, assessing, and solving medication-related problems, and providing clinical judgments as to the continuing effectiveness of individualized therapeutic plans and intended therapeutic outcomes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(3)">(3)</span> Conducting appropriate physical assessments, evaluating patient problems, and ordering and monitoring medications and laboratory tests in accordance with established standards of practice;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(4)">(4)</span> Monitoring patients and patient populations regarding the purposes, uses, effects, and pharmacoeconomics of their medications and related therapy;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(5)">(5)</span> Providing emergency first care, including cardiopulmonary resuscitation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(6)">(6)</span> Using clinical data to optimize therapeutic drug regimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#B(7)">(7)</span> Documenting interventions and evaluating pharmaceutical care outcomes.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#C">C.</span> The Board of Pharmacy shall determine whether the pharmacist meets the requirements of §§A and B of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D">D.</span> An authorized prescriber who has entered into a prescriber-pharmacist agreement shall submit to the Boards that regulate the authorized prescriber a copy of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(1)">(1)</span> The prescriber-pharmacist agreement;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(2)">(2)</span> Subsequent amendments made to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(2)(a)">(a)</span> Prescriber-pharmacist agreement; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(2)(b)">(b)</span> Protocols specified in the prescriber-pharmacist agreement; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(3)">(3)</span> Changes to participants of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(3)(a)">(a)</span> Prescriber-pharmacist agreement; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#D(3)(b)">(b)</span> Protocols specified in the prescriber-pharmacist agreement.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#E">E.</span> The Boards that regulate the authorized prescriber shall notify the authorized prescriber of any additional information needed within 30 days of the receipt of the submitted information.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F">F.</span> A licensed pharmacist who has entered into a prescriber-pharmacist agreement shall submit to the Board of Pharmacy a copy of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(1)">(1)</span> The prescriber-pharmacist agreement;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(2)">(2)</span> Subsequent amendments made to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(2)(a)">(a)</span> Prescriber-pharmacist agreement; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(2)(b)">(b)</span> Protocols specified in the prescriber-pharmacist agreement; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(3)">(3)</span> Changes to participants of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(3)(a)">(a)</span> Prescriber-pharmacist agreement; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#F(3)(b)">(b)</span> Protocols specified in the prescriber-pharmacist agreement.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#G">G.</span> The Board of Pharmacy shall determine whether a pharmacist added under <a class="internal-link " href="/us/md/exec/comar/10.34.29.04#F" title="">§F of this regulation</a> meets the requirements of §§A and B of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.04#H">H.</span> The Board of Pharmacy shall notify the pharmacist of any additional information needed within 30 days of the receipt of the submitted information.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.05" data-order="|10|34|29|.05|" data-ref-path="10|34|29|.05" class="h__section">.05 Guidelines for Use of Protocols.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#A">A.</span> On receipt of specific instructions from the authorized prescriber regarding a specific patient, the pharmacist may execute the authorized prescriber’s specific instructions even if the instructions deviate from the protocol.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#B">B.</span> The protocol may not prohibit the pharmacist from providing other pharmaceutical services that are within the pharmacist's scope of practice.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#C">C.</span> Documentation of activities performed under a protocol or the authorized prescriber’s specific instructions shall be maintained in such a manner that it is accessible to the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#C(1)">(1)</span> Authorized prescriber; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#C(2)">(2)</span> Pharmacist.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#D">D.</span> Documentation may be maintained in written or electronic form.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#E">E.</span> Oral communications between the authorized prescriber and pharmacist shall be summarized in the documentation maintained by the pharmacist and forwarded to the authorized prescriber.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#F">F.</span> Unless an alternative time period is stated in the prescriber-pharmacist agreement, the pharmacist shall inform the authorized prescriber within 48 hours if the pharmacist:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#F(1)">(1)</span> Modifies the dose or agent under the therapy management contract;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#F(2)">(2)</span> Detects an abnormal result from an assessment activity; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.05#F(3)">(3)</span> Initiates drug therapy under a written, disease-state specific protocol, for protocols by a licensed physician and pharmacist.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.06" data-order="|10|34|29|.06|" data-ref-path="10|34|29|.06" class="h__section">.06 Therapy Management Contracts.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#A">A.</span> A therapy management contract shall be signed by the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#A(1)">(1)</span> Authorized prescriber or authorized prescribers involved in the management of the patient under a prescriber-pharmacist agreement;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#A(2)">(2)</span> Pharmacist or pharmacists involved in the management of the patient under a prescriber-pharmacist agreement; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#A(3)">(3)</span> Patient receiving care under the therapy management contract.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B">B.</span> A therapy management contract shall contain:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(1)">(1)</span> A list of allowable substitutions of chemically dissimilar drugs, if any;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)">(2)</span> A statement that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(a)">(a)</span> None of the parties involved in the therapy management contract have been:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(a)(i)">(i)</span> Coerced into participating in the therapy management contract;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(a)(ii)">(ii)</span> Given economic incentives, excluding normal reimbursement for services rendered; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(a)(iii)">(iii)</span> Involuntarily required to participate in the therapy management contract; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(b)">(b)</span> The pharmacist shall notify the authorized prescriber under the terms of the prescriber-pharmacist agreement if the pharmacist:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(b)(i)">(i)</span> Modifies the dose or agent under the therapy management contract; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(2)(b)(ii)">(ii)</span> Detects an abnormal result from an assessment activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(3)">(3)</span> Notice to the patient stating:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(3)(a)">(a)</span> That the patient may terminate the therapy management contract at any time; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(3)(b)">(b)</span> The procedure by which the patient may terminate the therapy management contract;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(4)">(4)</span> A procedure for periodic review by the authorized prescriber of the drugs modified under the prescriber-pharmacist agreement or changed with the consent of the authorized prescriber;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(5)">(5)</span> A reference to the protocol or protocols under which the pharmacist shall act; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.34.29.06#B(6)">(6)</span> Exceptions or limitations to the protocol or protocols for the specific patient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.34.29.07" data-order="|10|34|29|.07|" data-ref-path="10|34|29|.07" class="h__section">.07 Fees.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.07#A">A.</span> Scope. This regulation governs authorized prescribers and pharmacists participating in drug therapy management or amendment of authorized prescribers and pharmacists that participate in the prescriber-pharmacist agreements relating to drug therapy management.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.34.29.07#B">B.</span> Fees. The Board of Pharmacy requires a fee for the prescriber-pharmacist agreement and protocol application (which includes review of the qualifications of the pharmacist participants) of $100 per prescriber-pharmacist agreement.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.34.28" aria-label="Chapter 28 Automated Medication Systems">
                <div class="h__ui">Previous</div>
                <span>Chapter 28 Automated Medication Systems</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.34.30" aria-label="Chapter 30 Change to Permit — Pharmacy or Wholesale Distribution Permit Holder">
                <div class="h__ui">Next</div>
                <span>Chapter 30 Change to Permit — Pharmacy or Wholesale Distribution Permit Holder</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
